Search

Our member companies generally support the recommendations found in the guidance but have concerns about the scope of hardness measurements and maximum break strength value.

CHPA and its member companies have an interest and expertise in dosage delivery devices and support FDA's efforts to develop guidance for industry on this important topic.

The American Cleaning Institute (ACI) and the Consumer Healthcare Products Association (CHPA) request that FDA withdraw its Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19).

This letter is submitted on behalf of CHPA, FMI, HDMA, and NACDS. The purpose of the letter is to express our united concern that the DEA’s proposed rule is not supported by existing evidence and will impose a significant burden on the regulated industry.

CHPA comments on issues associated with the public health benefit of certain drugs being available without a prescription, but only after intervention by a pharmacist.

We understand that FDA is considering a switch of a second generation antihistamine, from prescription to OTC status, over the objections of the company. CHPA opposes a policy to force switch over the objections of the drug sponsor.

This submission represents CHPA's detailed written comments as follow-up to the June meeting and is intended to complement the Association's oral presentation.

CHPA presentations at Food and Drug Administration OTC Part 15 hearing - Over-the-Counter Medications: A Success Story.

FDA announced a reopening of the administrative record for the rulemaking for OTC laxative drug products. CHPA sees this as an appropriate time to get clarification on an allowable statement of identity for OTC laxative drug products that contain fiber.